Omega Therapeutics, Inc.
OMGAQ
$0.0381
-$0.0069-15.33%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.61M | 2.13M | 2.36M | 989.00K | 831.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.61M | 2.13M | 2.36M | 989.00K | 831.00K |
| Cost of Revenue | 9.31M | 9.34M | 15.42M | 12.22M | 12.51M |
| Gross Profit | -6.70M | -7.21M | -13.06M | -11.23M | -11.68M |
| SG&A Expenses | 9.73M | 9.37M | 7.40M | 9.47M | 11.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.03M | 18.71M | 22.81M | 21.69M | 23.73M |
| Operating Income | -16.42M | -16.58M | -20.45M | -20.70M | -22.90M |
| Income Before Tax | -16.44M | -16.31M | -20.13M | -20.21M | -22.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.44M | -16.31M | -20.13M | -20.21M | -22.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.44M | -16.31M | -20.13M | -20.21M | -22.25M |
| EBIT | -16.42M | -16.58M | -20.45M | -20.70M | -22.90M |
| EBITDA | -15.99M | -16.14M | -20.01M | -20.28M | -22.46M |
| EPS Basic | -0.30 | -0.30 | -0.37 | -0.37 | -0.40 |
| Normalized Basic EPS | -0.19 | -0.18 | -0.23 | -0.23 | -0.25 |
| EPS Diluted | -0.30 | -0.30 | -0.37 | -0.37 | -0.40 |
| Normalized Diluted EPS | -0.19 | -0.18 | -0.23 | -0.23 | -0.25 |
| Average Basic Shares Outstanding | 55.16M | 55.15M | 55.15M | 55.14M | 55.14M |
| Average Diluted Shares Outstanding | 55.16M | 55.15M | 55.15M | 55.14M | 55.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |